Scarica l'app Stockscreener
11.59
2.52%
0.285
Dopo l'orario di chiusura:
11.45
-0.14
-1.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
FDA delays Kalvista’s sebetralstat decision due to resource constraints By Investing.com - Investing.com Nigeria
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive
FDA delays Kalvista’s sebetralstat decision due to resource constraints - Investing.com
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - BioSpace
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Pat - GuruFocus
KalVista’s oral HAE treatment shows efficacy for breakthrough attacks By Investing.com - Investing.com Canada
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues - MarketScreener
Kalvista stock steady as JMP reiterates $19 target amid FDA delay - Investing.com Canada
Kalvista stock steady as JMP reiterates $19 target amid FDA delay By Investing.com - Investing.com South Africa
DRI Healthcare Trust Reports FDA Delay on KalVista’s Sebetralstat Decision - MSN
FDA won’t meet PDUFA goal date for sebetralstat - The Pharma Letter
DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals' Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints - Weekly Voice
US FDA extends review of KalVista's swelling disorder drug due to heavy workload - Reuters
FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision - Bloomberg
FDA cites ‘resource constraints' in delay of local biotech's drug approval decision - The Business Journals
KalVista (KALV) Shares Decline as FDA Delays Drug Review - GuruFocus
FDA delays decision on KalVista’s HAE treatment sebetralstat By Investing.com - Investing.com India
KalVista said FDA will not meet review date for sebetralstat (KALV) - Seeking Alpha
KalVista (KALV) Awaits FDA Decision on Sebetralstat Due to Revie - GuruFocus
Kalvista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date For Sebetralstat NDA - marketscreener.com
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints - Business Wire
Two Sigma Investments LP Has $114,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KALV’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Research Analysts Issue Forecasts for KALV FY2026 Earnings - Defense World
Two Sigma Advisers LP Sells 15,500 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - BioSpace
KalVista Pharmaceuticals to Present New Sebetralstat Data at the - GuruFocus
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KALV Stock News - GuruFocus
Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 - BioSpace
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - marketscreener.com
KalVista (KALV) Shows Promising Sebetralstat Results for Heredit - GuruFocus
KalVista (KALV) Shows Promising Sebetralstat Results for Hereditary Angioedema | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highligh - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management | KALV Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Deutsche Bank AG Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):